ATA Guidelines Tools

Anaplastic Thyroid Cancer ATA 2021

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1441026

Contents of this Issue

Navigation

Page 22 of 27

23 Pathologic Assessment ATC? Undifferentiated Neoplasm NOT ATC Y Y N N Histology & IHC, assess as indicated, including: • TTF-1, Tg, PAX8 • BRAF V600E # Differential Diagnosis: • Lymphoma • Metastasis • Sarcoma • Squamous call carcinoma lung/head and neck • Other + Assess with US to consider/exclude benign conditions (e.g., hemorrhage into cyst). # Tumor IHC for BRAF V600E or circulating/free DNA assessment are considered sufficiently robust for guiding initial clinical care but require confirmation by tumor DNA sequencing.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Anaplastic Thyroid Cancer ATA 2021